Challenges in Protein Production and How to Overcome Them

Published: 9月 8, 2026

Recombinant protein production is fundamental to biopharmaceutical development and biotechnology research; however, achieving high yields of functional proteins remains challenging. Factors such as improper protein folding, aggregation, host-cell limitations, proteolytic degradation, and low expression levels can significantly affect product quality and process efficiency. Careful optimization of expression systems, culture conditions, purification strategies, and analytical methods is therefore essential to obtain stable, biologically active proteins.2

Key Takeaways

  • Protein production can be affected by challenges such as low yield, protein aggregation, incorrect folding, degradation, and poor solubility.
  • Careful optimization of expression systems, culture conditions, and purification strategies is critical for producing high-quality recombinant proteins.
  • Process variability and host-cell limitations can impact protein quality, stability, and reproducibility across development workflows.
  • Laboratory automation supports reproducible protein production by improving workflow standardization, throughput, and process optimization.

Common Protein Expression Challenges

Challenge Description
Low protein yield Insufficient expression resulting in poor recovery of the target protein.
Protein aggregation Formation of insoluble aggregates or inclusion bodies that reduce functional protein production.
Incorrect protein folding Misfolded proteins often lose biological activity.
Proteolytic degradation Host-cell proteases can break down the expressed protein.
Lack of post-translational modifications (PTMs) Some expression hosts cannot perform essential modifications such as glycosylation.
Protein toxicity Expression of certain proteins can negatively affect host-cell growth and viability.
Poor solubility Expressed proteins may remain insoluble, complicating purification.
Protein instability Denaturation, oxidation, or degradation can occur during purification and storage.
Batch-to-batch variability Differences in process conditions can affect protein quality and reproducibility.2

Table 1. Common protein expression challenges that can affect recombinant protein yield, quality, stability, and reproducibility.

How automation helps:

Standardized workflow execution, precise liquid handling and high-throughput screening support reproducible protein production and process optimization.

Our Role in Addressing Protein Production Challenges

Laboratory automation can significantly mitigate many protein production challenges by providing precise liquid handling, standardized workflow execution, and high-throughput process optimization. Automated platforms such as the Biomek i-Series Automated Liquid Handlers enable parallel screening of expression conditions, purification parameters, and formulation factors, reducing human error and improving reproducibility.

Biomek i3 Benchtop Liquid Handler

Biomek i3 Benchtop Liquid Handler

Biomek i5 Automated Workstation

Biomek i5 Automated Workstation

Biomek i7 Automated Workstation

Biomek i7 Automated Workstation

View References
  1. Alhammad LA, Ainosah TK, Ahmad AM et al. (2023). The impact of laboratory automation on efficiency and accuracy in healthcare settings. International Journal Of Community Medicine And Public Health, 11(1), 459–463.
  2. Bhatwa A, Wang W, Hassan YI et al. (2021). Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications. Frontiers in Bioengineering and Biotechnology. 9:630551.
  3. Blass E, Ott PA. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews Clinical Oncology. 18, 215–229.
  4. Cha H, Park J-H. (2021). Recombinant Human Erythropoietin Production in Chinese Hamster Ovary Cells Is Enhanced by Supplementation of α-Helix Domain of 30Kc19 Protein. Applied Sciences. 11(22):11009.
  5. Chabot et al. (2026). Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. Volume 302(1).
  6. Chen Y-L, Xie X-X, Zhong N et al. (2023). Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies. International Journal of Molecular Sciences. 24(5):4307.
  7. Creangă EC, Stan R, Nicolae AC et al. (2025). Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications. Pharmaceutics. 17(9):1190.
  8. Echelard Y, Meade HM, Ziomek CA. (2006). Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals. BioPharm International. 19(8).
  9. Gupta V, Sengupta M, Prakash J et al. (2017). Production of Recombinant Pharmaceutical Proteins. In: Basic and Applied Aspects of Biotechnology. Springer, Singapore.
  10. Gupta V et al. (2016). Production of Recombinant Pharmaceutical Proteins. Basic and Applied Aspects of Biotechnology. 77–101.
  11. Hernandez SI, Berezin CT, Miller KM et al. (2024). Sequencing Strategy to Ensure Accurate Plasmid Assembly. ACS Synthetic Biology. 13(12):4099-4109.
  12. Hong M, Li T, Xue W et al. (2022). Genetic engineering of baculovirus-insect cell system to improve protein production. Frontiers in Bioengineering and Biotechnology. 10:994743.
  13. Hou L, Zhang XY, Li Y et al. (2016). Rapid Screening of Recombinant Plasmids by Direct Colony Quantitative Real-Time PCR. Advances in Bioscience and Biotechnology. 7, 428-433.
  14. Beckman Coulter. Nanoliter-Scale DNA Assembly with the Echo 525 Liquid Handler Application Note.
  15. Jayakrishnan A, Wan Rosli WR, Tahir ARM et al. (2024). Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. Sci. 6(1):9.
  16. Kumar V, Barwal A, Sharma N et al. (2024). Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 14, 112.
  17. Mahmood F, Xu R, Awan MUN et al. (2023). HBV Vaccines: Advances and Development. Vaccines. 11(12):1862.
  18. Martins JT, Bourbon AI, Pinheiro AC et al. (2018). Protein-Based Structures for Food Applications: From Macro to Nanoscale. Frontiers in Sustainable Food Systems. 2:77.
  19. Ojima-Kato T. (2025). Advances in recombinant protein production in microorganisms and functional peptide tags. Bioscience, Biotechnology, and Biochemistry. 89(1).
  20. Pastores GM. (2010). Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease. BioDrugs. 24, 41–47.
  21. Rosano GL, Morales ES, Ceccarelli EA. (2019). New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science. 28(8):1412-1422.
  22. Shanmugaraj B, Bulaon CJI, Phoolcharoen W. (2020). Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 9(7):842.
  23. Shilling PJ, Mirzadeh K, Cumming AJ et al. (2020). Improved designs for pET expression plasmids increase protein production yield in Escherichia coli. Communications Biology. 3, 214.
  24. Wang W. (2015). Advanced protein formulations. Protein Science. 24(7):1031-9.
  25. Wu et al. (2025). Automating an Adeno-associated Virus (AAV) Functional Assay Using the Biomek i7 Liquid Handler with Integrated Vi-CELL BLU Analyzer. Application Note.
  26. Swain SM, Shastry M, Hamilton E. (2023). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2):101-126.
  27. Konkle B, Oldenburg J, Pasi J et al. (2023). Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
  28. Gao Y, Yin Y, Xie P et al. (2025). Interferon in Liver Diseases: Recent Advances. Advances in Therapy. 42, 4210–4223.

Explore Related Protein Production Topics

Continue exploring the technologies, workflows, and applications that support efficient and scalable recombinant protein production.

FAQ on Challenges in Protein Production

What are the most critical bottlenecks in protein production workflows and how can they be prevented?

Common bottlenecks in protein production include low expression levels, protein aggregation, incorrect folding, proteolytic degradation, inadequate post-translational modifications, protein instability, and process variability. These challenges can be reduced by optimizing expression systems and culture conditions, selecting appropriate host cells, improving purification and formulation strategies, and implementing standardized, automated workflows to enhance yield, quality, and reproducibility.2

What are the best strategies to reduce variability in protein production experiments?

Reducing variability in protein production requires a combination of standardized experimental conditions, robust process controls, and laboratory automation.

Automation further reduces variability by eliminating many sources of human error associated with manual pipetting, sample handling, and workflow execution.

In addition, implementing routine analytical monitoring, quality controls, and data-driven optimization strategies helps identify process deviations early.1,2

How can recombinant protein production be optimized for higher yield and reproducibility?

Recombinant protein production can be optimized through host selection, expression system engineering, process optimization, and workflow automation:

  • Choosing the appropriate expression host
  • Optimizing gene and vector design
  • Improving protein solubility and folding
  • Optimizing culture conditions
  • Implementing robust purification methods

High-throughput screening, clone selection, process monitoring, and automated workflows further enhance protein yield, quality, and reproducibility while reducing batch-to-batch variability.2

Basse Hofzumahaus 

Basse Hofzumahaus 

Product Marketing Manager 

About the author:

Basse Hofzumahaus brings 15+ years of experience in life sciences, across academia, R&D, and product management. With a PhD and M.Sc. in Biotechnology, he connects scientific depth with a focus on upstream bioprocessing, microbial fermentation, CHO workflows, clone screening, and microbioreactor development. 

Talk to an Expert